Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of SBRT combined with cardonilizumab and lenvastinib in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus
Hepatocellular Carcinoma Non-resectable|Portal Vein Tumor Thrombus|Immune Checkpoint Inhibitors
DRUG: Cadonilimab|RADIATION: Stereotactic radiotherapy|DRUG: Renvatinib
Objective response rate(ORR), ORR is proportion of patients with complete response(CR) or partial response(PR) assessed by investigators according to RECIST v1.1., Up to approximately 2 years
3-month PFS rate, 3-month PFS rate is the percentage of patients whose disease has not progressed within 3 months., Up to approximately 2 years|progression-free survival (PFS), Progression-free survival (PFS) is defined as the time from the first dose of Cadonilimab until documentation of PD (as per RECIST v1.1) or death due to any cause, whichever occurs first., Up to approximately 2 years|Disease control rate (DCR), DCR is proportion of patients with complete response, partial response or stable disease assessed by investigators according to RECIST v1.1., Up to approximately 2 years|Duration of response (DOR), Duration of Response (DOR) is defined as the time between the first assessment of a tumor as Complete Response（CR）or Partial Response（PR）and the first assessment of Progressive Disease (PD) or death from any cause., Up to approximately 2 years|Overall Survival (OS), Overall survival (OS) is defined as the time from the first dose of Cadonilimab until death due to any cause, Up to approximately 2 years
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of SBRT combined with cardonilizumab and lenvastinib in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus